Prolyl Hydroxylases and Therapeutics

Antioxidants and Redox Signaling

Volumn 12, Issue 4, 2010, Pages 431-433

  Smith, Thomas G ^a,b   Talbot, Nick P ^a,c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITOR; HYPOXIA INDUCIBLE FACTOR; IRON; OXYGEN; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE INHIBITOR; UNCLASSIFIED DRUG;

ANEMIA; CELL PROTECTION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENZYME ACTIVITY; HUMAN; HUNTINGTON CHOREA; HYPOXIA; IRON METABOLISM; ISCHEMIC HEART DISEASE; METABOLIC STRESS; NEOPLASM; NEUROPROTECTION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; STROKE; TRANSCRIPTION REGULATION;

ANEMIA; DIOXYGENASES; DRUG DISCOVERY; ENZYME INHIBITORS; HOMEOSTASIS; HUMANS; HYPERTENSION, PULMONARY; IRON; MYOCARDIAL ISCHEMIA; NEOPLASMS; NEUROPROTECTIVE AGENTS; OXYGEN; PROCOLLAGEN-PROLINE DIOXYGENASE; STROKE;

EID: 75149138761     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2009.2901     Document Type: Review

References (13)

1. Bruick RK and McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294: 1337-1340, 2001.
2. De Tullio MC. How does ascorbic acid prevent scurvy? A survey of the nonantioxidant functions of vitamin C. In: Vitamin C, edited by Asard H, May JM, and Smirnoff N. Oxford, UK: BIOS Scientific Publishers, 2004, pp. 159-171.
3. Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole DR, Mukherji M, Metzen E, Wilson MI, Dhanda A, Tian YM, Masson N, Hamilton DL, Jaakkola P, Barstead R, Hodgkin J, Maxwell PH, Pugh CW, Schofield CJ, and Ratcliffe PJ. C. elegans EGL-9 and mammalian ho-mologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107: 43-54, 2001.
4. Harten SK, Ashcroft M, and Maxwell PH. Prolyl hydroxy-lase domain inhibitors: a route to HIF activation and neu-roprotection. Antioxid Redox Signal 12: 459-480, 2010.
5. Joyner MJ and Johnson BD. Iron lung? New ideas about hyp-oxic pulmonary vasoconstriction. J Physiol 586: 5837-5838, 2008.
6. Melnikova I. Anaemia therapies. Nat Rev Drug Disc 5: 627-628, 2006.
7. Mole DR. Iron homeostasis and its interaction with prolyl hydroxylases. Antioxid Redox Signal 12: 445-458, 2010.
8. Nagel S, Talbot NP, Mecinović J, Smith TG, Buchan AM, and Schofield CJ. Therapeutic manipulation of the HIF hydroxy-lases. Antioxid Redox Signal 12: 481-501, 2010.
9. Niatsetskaya Z, Basso M, Speer RE, McConoughey SJ, Coppola G, Ma TC, and Ratan RR. HIF prolyl hydroxylase inhibitors prevent neuronal death induced by mitochondrial toxins: therapeutic implications for Huntington's disease and Alzheimer's disease. Antioxid Redox Signal 12: 435-443, 2010.
10. Smith TG, Balanos GM, Croft QP, Talbot NP, Dorrington KL, Ratcliffe PJ, and Robbins PA. The increase in pulmonary arterial pressure caused by hypoxia depends on iron status. J Physiol 586: 5999-6005, 2008.
11. Smith TG, Brooks JT, Balanos GM, Lappin TR, Layton DM, Leedham DL, Liu C, Maxwell PH, McMullin MF, McNa-mara CJ, Percy MJ, Pugh CW, Ratcliffe PJ, Talbot NP, Treacy M, and Robbins PA. Mutation of von Hippel-Lindau tumour suppressor and human cardiopulmonary physiology. PLoS Med 3: e290, 2006.
12. Smith TG, Robbins PA, and Ratcliffe PJ. The human side of hypoxia-inducible factor. Br J Haematol 141: 325-334, 2008.
13. Smith TG, Talbot NP, Privat C, Rivera-Ch M, Nickol AH, Ratcliffe PJ, Dorrington KL, León-Velarde F, and Robbins PA. Effects of iron supplementation and depletion on hy-poxic pulmonary hypertension: two randomized controlled trials. JAMA 302: 1444-1450, 2009.